JP2021519308A5 - - Google Patents
Info
- Publication number
- JP2021519308A5 JP2021519308A5 JP2020551963A JP2020551963A JP2021519308A5 JP 2021519308 A5 JP2021519308 A5 JP 2021519308A5 JP 2020551963 A JP2020551963 A JP 2020551963A JP 2020551963 A JP2020551963 A JP 2020551963A JP 2021519308 A5 JP2021519308 A5 JP 2021519308A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- groups
- cancer
- alkoxy
- haloalkyl
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650151P | 2018-03-29 | 2018-03-29 | |
| US62/650,151 | 2018-03-29 | ||
| PCT/US2019/024976 WO2019191667A1 (en) | 2018-03-29 | 2019-03-29 | Imidazopiperazine inhibitors of transcription activating proteins |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021519308A JP2021519308A (ja) | 2021-08-10 |
| JP2021519308A5 true JP2021519308A5 (https=) | 2022-03-30 |
| JPWO2019191667A5 JPWO2019191667A5 (https=) | 2022-03-30 |
| JP7387627B2 JP7387627B2 (ja) | 2023-11-28 |
Family
ID=68057632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551963A Active JP7387627B2 (ja) | 2018-03-29 | 2019-03-29 | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11058688B2 (https=) |
| EP (1) | EP3773587A4 (https=) |
| JP (1) | JP7387627B2 (https=) |
| KR (1) | KR102815607B1 (https=) |
| CN (1) | CN112165944B (https=) |
| AU (2) | AU2019245403B2 (https=) |
| BR (1) | BR112020019824A2 (https=) |
| CA (1) | CA3095367A1 (https=) |
| IL (1) | IL277628A (https=) |
| RU (1) | RU2020131507A (https=) |
| WO (1) | WO2019191667A1 (https=) |
| ZA (1) | ZA202006092B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019245403B2 (en) | 2018-03-29 | 2025-02-06 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| AU2021259814B2 (en) * | 2020-04-25 | 2023-09-28 | Pharmablock Sciences (Nanjing), Inc. | CBP/EP300 inhibitor and use thereof |
| JP7777131B2 (ja) * | 2020-10-02 | 2025-11-27 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 転写活性化タンパク質のイミダゾピペラジン阻害剤 |
| WO2022072648A1 (en) * | 2020-10-02 | 2022-04-07 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| KR102910851B1 (ko) * | 2021-04-21 | 2026-01-09 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | 이미다졸 함유 축합고리계 유도체, 이의 제조방법 및 이의 의약적 용도 |
| CN113429427A (zh) * | 2021-07-05 | 2021-09-24 | 湖南南新制药股份有限公司 | 杂环化合物及其制备方法和药物用途 |
| CN115724857B (zh) * | 2021-08-25 | 2024-06-21 | 杭州禹泓医药科技有限公司 | 一种芳杂环类化合物、含其的药物组合物及其应用 |
| CN116410211A (zh) * | 2021-12-29 | 2023-07-11 | 山东新时代药业有限公司 | 一种苯并呋喃类化合物 |
| TW202340164A (zh) * | 2022-01-21 | 2023-10-16 | 大陸商深圳默元生物科技有限公司 | Ｎ－羥基喹啉甲醯胺化合物及其用途 |
| WO2023235809A1 (en) * | 2022-06-02 | 2023-12-07 | Eli Lilly And Company | Cgas inhibitors |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1537114B8 (en) | 2002-08-07 | 2007-10-03 | Novartis AG | Organic compounds as agents for the treatment of aldosterone mediated conditions |
| AU2003284596A1 (en) | 2002-11-22 | 2004-06-18 | Takeda Pharmaceutical Company Limited | Imidazole derivative, process for producing the same, and use |
| MX2008015008A (es) | 2006-05-26 | 2008-12-05 | Novartis Ag | INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA. |
| US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| ATE545647T1 (de) | 2006-12-22 | 2012-03-15 | Actelion Pharmaceuticals Ltd | 5,6,7,8-tetrahydro-imidazoä1,5-aüpyrazinderivat |
| US8859538B2 (en) | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| EP2170350B1 (en) | 2007-06-21 | 2013-09-11 | Cara Therapeutics, Inc. | Substituted imidazoheterocycles |
| CN101417999A (zh) | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| CN101468988A (zh) * | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| KR20110036069A (ko) | 2008-06-25 | 2011-04-06 | 액테리온 파마슈티칼 리미티드 | 5,6,7,8-테트라히드로-이미다조[1,5-ａ]피라진 화합물 |
| EA021293B1 (ru) * | 2008-12-08 | 2015-05-29 | Джилид Коннектикут, Инк. | ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| EP2528918B1 (en) | 2010-01-29 | 2014-09-10 | Nerviano Medical Sciences S.r.l. | 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| US9145418B2 (en) | 2011-10-07 | 2015-09-29 | Nerviano Medical Sciences S.R.L. | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors |
| CN103087067A (zh) * | 2012-08-02 | 2013-05-08 | 盛世泰科生物医药技术(苏州)有限公司 | 作为二肽基酶抑制剂的化合物及其组合物，以及它们的用途 |
| EP2920173B1 (en) | 2012-10-18 | 2016-11-23 | Bristol-Myers Squibb Company | Tetrahydroimdidazopyrazine derivatives as cgrp receptor antagonists |
| WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| JP2016525503A (ja) * | 2013-06-28 | 2016-08-25 | アッヴィ・インコーポレイテッド | ブロモドメイン阻害剤 |
| WO2016055028A1 (en) | 2014-10-10 | 2016-04-14 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| US9763922B2 (en) * | 2014-11-27 | 2017-09-19 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| AU2017252276A1 (en) | 2016-04-18 | 2018-11-15 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| MA45122A (fr) | 2016-05-24 | 2019-04-10 | Constellation Pharmaceuticals Inc | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer |
| EP3464286B1 (en) * | 2016-05-24 | 2021-08-18 | Genentech, Inc. | Pyrazolopyridine derivatives for the treatment of cancer |
| AU2019245403B2 (en) | 2018-03-29 | 2025-02-06 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
-
2019
- 2019-03-29 AU AU2019245403A patent/AU2019245403B2/en active Active
- 2019-03-29 CA CA3095367A patent/CA3095367A1/en active Pending
- 2019-03-29 EP EP19777484.7A patent/EP3773587A4/en active Pending
- 2019-03-29 BR BR112020019824-2A patent/BR112020019824A2/pt not_active Application Discontinuation
- 2019-03-29 WO PCT/US2019/024976 patent/WO2019191667A1/en not_active Ceased
- 2019-03-29 JP JP2020551963A patent/JP7387627B2/ja active Active
- 2019-03-29 CN CN201980035368.2A patent/CN112165944B/zh active Active
- 2019-03-29 US US16/370,404 patent/US11058688B2/en active Active
- 2019-03-29 RU RU2020131507A patent/RU2020131507A/ru unknown
- 2019-03-29 KR KR1020207031004A patent/KR102815607B1/ko active Active
-
2020
- 2020-09-27 IL IL277628A patent/IL277628A/en unknown
- 2020-10-01 ZA ZA2020/06092A patent/ZA202006092B/en unknown
-
2021
- 2021-05-21 US US17/327,217 patent/US12186324B2/en active Active
-
2024
- 2024-11-06 US US18/938,730 patent/US20250127792A1/en active Pending
-
2025
- 2025-04-29 AU AU2025202971A patent/AU2025202971A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519308A5 (https=) | ||
| JP2015534580A5 (https=) | ||
| JP2016502504A5 (https=) | ||
| FI3328827T3 (fi) | Glutamiinianalogien aihiolääkkeitä | |
| JP2015534578A5 (https=) | ||
| RU2020111366A (ru) | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения | |
| MX2021005214A (es) | Farmacos anti-estrogenicos tetrahidro-1h-pirido [3,4-b] indol. | |
| JP2017510641A5 (https=) | ||
| JP2017186337A5 (https=) | ||
| JP2018536624A5 (https=) | ||
| JP2015534579A5 (https=) | ||
| JP2017517506A5 (https=) | ||
| MX338831B (es) | Moduladores selectivos de receptores de androgenos. | |
| WO2009105214A3 (en) | Selective androgen receptor modulators | |
| WO2010118287A8 (en) | Selective androgen receptor modulators | |
| JP2018516966A5 (https=) | ||
| JP2015527318A5 (https=) | ||
| JP2014055156A5 (https=) | ||
| JP2019524714A5 (https=) | ||
| AU2012288626A8 (en) | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as EGFR modulators useful for treating cancer | |
| JP2013523784A5 (https=) | ||
| JP2017509586A5 (https=) | ||
| MY183927A (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| JP2019527239A5 (https=) | ||
| JP2015502926A5 (https=) |